Jump to main content
Jump to site search

Issue 9, 2017
Previous Article Next Article

4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade

Author affiliations

Abstract

The NF-κB signaling pathway is a validated oncological target. Here, we applied scaffold hopping to IMD-0354, a presumed IKKβ inhibitor, and identified 4-hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide (4) as a nM-inhibitor of the NF-κB pathway. However, both 4 and IMD-0354, being potent inhibitors of the canonical NF-κB pathway, were found to be inactive in human IKKβ enzyme assays.

Graphical abstract: 4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade

Back to tab navigation

Supplementary files

Article information


Submitted
30 May 2017
Accepted
22 Aug 2017
First published
25 Aug 2017

Med. Chem. Commun., 2017,8, 1850-1855
Article type
Research Article

4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade

A. C. Pippione, A. Federico, A. Ducime, S. Sainas, D. Boschi, A. Barge, E. Lupino, M. Piccinini, M. Kubbutat, J. Contreras, C. Morice, S. Al-Karadaghi and M. L. Lolli, Med. Chem. Commun., 2017, 8, 1850
DOI: 10.1039/C7MD00278E

Search articles by author

Spotlight

Advertisements